Significance of Serum Tumor Necrosis Factor-Alpha and its Combination with Her-2 Codon 655 Polymorphism in the Diagnosis and Prognosis of Breast Cancer
Free accessResearch articleFirst published online July, 2010
Significance of Serum Tumor Necrosis Factor-Alpha and its Combination with Her-2 Codon 655 Polymorphism in the Diagnosis and Prognosis of Breast Cancer
The present study was conducted to clarify the diagnostic and prognostic significance of TNF-alpha and its combination with HER-2 Ile655Val SNP in breast cancer.
Methods
In this case-control study, 56 consecutive patients with primary breast cancer were prospectively evaluated. The control group consisted of 45 healthy women. Serum concentrations of TNF-alpha were measured by quantitative sandwich enzyme immunoassay (ELISA). HER-2 SNP was genotyped using the PCR-RFLP method.
Results
Serum TNF-alpha was significantly increased in patients compared to controls. ROC analysis indicated a cutoff point of 11.00 pg/mL to classify breast cancer patients (sensitivity, 86%; specificity, 71%). Elevated TNF-alpha levels were associated with larger, poorly differentiated, invasive and advanced-stage tumors, and >3 positive lymph nodes. Regarding HER-2 SNP, patients with Ile-Val and Val-Val genotypes had significant TNF-α elevation compared with homozygous Ile-Ile patients. In multivariate analysis, high serum TNF-alpha remained an independent prognostic factor of worse overall survival; its combination with Val-Val genotype predicted a worse prognosis than high TNF-alpha alone.
Conclusions
Serum TNF-a could be used clinically as a useful tumor marker for diagnosis, disease extent and outcome of breast cancer. The negative impact on survival seems to be enhanced through the interaction with HER-2 Ile655Val SNP.
AndersonG.M., NakadaM.T., DeWitteM.Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer.Curr Opin Pharmacol2004; 4: 314–20.
4.
ThomsenL.L., LawtonF.G., KnowlesR.G.Nitric oxide synthase activity in human gynecological cancer.Cancer Res1994; 54: 1352–4.
5.
JaiswalM., LaRussoN.F., BurgartL.J., GoresG.J.Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism.Cancer Res2000; 60: 184–90.
6.
CuiL.F., GuoX.J., WeiJ.Overexpression of TNF-α and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations.Histopathology2008; 53: 381–8.
7.
HanahanD., WeinbergR.A.The hallmarks of cancer.Cell2000; 100: 57–70.
8.
SzlosarekP., CharlesK.A., BalkwillF.R.Tumour necrosis factor-alpha as a tumour promoter.Eur J Cancer2006; 42: 745–50.
9.
SlamonD.J., GodolphinW., JonesL.A.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science1989; 244: 707–12.
10.
RevillionF., BonneterreJ., PeyratJ P.ERB2 oncogene in human breast cancer and its clinical significance.Eur J Cancer1998; 34: 791–808.
11.
MenardS., PupaS.M., CampiglioM., TagliabueE.Biologic and therapeutic role of HER2 in cancer.Oncogene2003; 22: 6570–8.
12.
RossJ.S., FletcherJ.A., LinetteG.P.The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.Oncologist2003; 8: 307–25.
13.
BaselgaJ., NortonL., AlbanellJ., KimY.M., MendelsohnJ.Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.Cancer Res1998; 58: 2825–31.
14.
ZhouB.P., HuM.C., MillerS.A.HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kB pathway.J Biol Chem2000; 275: 8027–31.
15.
PapewalisJ., NikitinA., RajewkyM.F.G to A polymorphism at amino acid codon 655 of the human erbB-2/HER-2 gene.Nucleic Acids Res1991; 19: 5452.
16.
TakanoK., OgasaharaK., KanedaH.Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants.J Mol Biol1995; 254: 62–76.
17.
XieD., ShuX., DengZ.Population-based, case-control study of HER-2 genetic polymorphism and breast cancer risk.J Natl Cancer Inst2000; 92: 412–7.
18.
KalemiT., LambropoulosA., GueorguievM.The association of p53 mutations and p53 codon 72, Her2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece.Cancer Lett2005; 222: 57–65.
19.
KeshavaC., McCanliesE.C., KeshavaN., WolffM.S., WestonA.Distribution of HER2V655 genotypes in breast cancer cases and controls in the United States.Cancer Lett2001; 173: 37–41.
20.
RutterJ.L., ChatterjeeN., WacholderS., StruewingJ.The HER2 I655V polymorphism and breast cancer risk in Ashkenazim.Epidemiology2003; 14: 694–700.
21.
ZuborP., VojvodovaA., DankoJ.HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.Neoplasma2006; 3: 49–55.
22.
AmeyawM., TayebM., ThorntonN.Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer.J Hum Genet2002; 47: 172–5.
23.
PapadopoulouE., SimopoulosK., TripsianisG.Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.Neoplasma2007; 54: 367–81.
24.
PapadopoulouE., TripsianisG., AnagnostopoulosK.The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.Neoplasma2008; 55: 113–21.
25.
BloomH.J.G., RichardsonW.W.Histological grading and prognosis in breast cancer.Br J Cancer1957; 11: 359–77.
26.
Union International contre le Cancer.UICC TNM classification of malignant tumors, 4th ed.Springer-Verlag, Berlin1992.
27.
SivridisE., KoukourakisM.I., ZoisC.E.LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas.Am J Pathol2010; 176: 2477–89.
28.
BerberogluU., YildirimE., CelenO.Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer.Int J Biol Markers2004; 19: 130–4.
29.
TesarováP., KalousováM., JáchymováM., MestekO., PetruzelkaL., ZimaT.Soluble TNF and IL-2 receptors in patients with breast cancer.Med Sci Monit2000; 6: 661–7.
30.
DaraïE., DetchevR., HugolD., QuangN.T.Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.Hum Reprod2003; 18: 1681–5.
31.
YoshidaN., IkemotoS., NaritaK.Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma.Br J Cancer2002; 86: 1396–400.
32.
MichalakiV., SyrigosK., CharlesP., WaxmanJ.Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer.Br J Cancer2004; 90: 2312–6.
33.
KarayiannakisA.J., SyrigosK.N., PolychronidisA., PitiakoudisM., BounovasA., SimopoulosK.Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients.Anticancer Res2001; 21: 1355–8.
34.
JablonskaE., PiotrowskiL., GrabowskaZ.Serum levels of IL-1b, IL-6, TNF-α, sTNF-RI and CRP in patients with oral cavity cancer.Pathol Oncol Res1997; 3: 126–9.
35.
MantovaniG., MacciòA., MuraL.Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites.J Mol Med2000; 78: 554–61.
36.
SatiH.I., GreavesM., ApperleyJ.F., RussellR.G., CroucherP.I.Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma.Br J Haematol1999; 104: 350–7.
37.
WarzochaK., RibeiroP., RenardN.Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas.Cancer Immunol Immunother2000; 49: 469–75.
38.
NaylorM.S., StampG.W., FoulkesW.D., EcclesD., BalkwillF.R.Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression.J Clin Invest1993; 91: 2194–206.
39.
MalikS.T., NaylorM.S., EastN., OliffA., BalkwillF.R.Cells secreting tumour necrosis factor show enhanced metastasis in nude mice.Eur J Cancer1990; 26: 1031–4.
40.
CubillosS., ScallonB., FeldmannM., TaylorP.Effect of blocking TNF on IL-6 levels and metastasis in a B16–BL6 melanoma/mouse model.Anticancer Res1997; 17: 2207–11.
41.
QinZ., Krüger-KrasagakesS., KunzendorfU., HockH., DiamantsteinT., BlankensteinT.Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis.J Exp Med1993; 178: 355–60.
42.
LeekR.D., LandersR., FoxS.B., NgF., HarrisA.L., LewisC.E.Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma.Br J Cancer1998; 77: 2246–51.
MillerA., KraiemZ., SobelE., LiderO., LahatN.Modulation of human leukocyte antigen and intracellular adhesion molecule-1 surface expression in malignant and nonmalignant human thyroid cells by cytokines in the context of extracellular matrix.Thyroid2000; 10: 945–50.
45.
KawashimaA., KawaharaE., TokudaR., NakanishiI.Tumour necrosis factor-alpha provokes upregulation of alpha2beta1 and alpha5beta1 integrins, and cell migration in OST osteosarcoma cells.Cell Biol Int2001; 25: 319–29.
46.
NozawaF., HirotaM., OkabeA.Tumor necrosis factor alpha acts on cultured human vascular endothelial cells to increase the adhesion of pancreatic cancer cells.Pancreas2000; 21: 392–8.
47.
CarpenterP.M., GatanagaT., NguyenH.P., HiserodtJ.C.Lymphocyte and monocyte-induced motility of MCF-7 cells by tumor necrosis factor-alpha.Int J Cancer1997; 71: 64–70.
48.
VarelaL.M., Stangle-CastorN.C., ShoemakerS.F., Shea-EatonW.K., IpM.M.TNFalpha induces NFkappaB/p50 in association with the growth and morphogenesis of normal and transformed rat mammary epithelial cells.J Cell Physiol2001; 188: 120–31.
49.
MussH.B., ThorA.D., BerryD.A.c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.N Engl J Med1994; 330: 1260–6.
50.
HudziakR.M., LewisG.D., ShalabyM.R.Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells.Proc Natl Acad Sci U S A1988; 85: 5102–6.
51.
SaglamS., SuzmeR., GurdolF.Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients.Int J Biol Markers2009; 24: 142–6.
52.
LichtensteinA., BerensonJ., GeraJ.F.Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.Cancer Res1990; 50: 7364–70.
53.
BalkwillF.TNF-alpha in promotion and progression of cancer.Cancer Metastasis Rev2006; 25: 409–16.
54.
ChenG., GoeddelD.V.TNF-R1 signaling: a beautiful pathway.Science2002; 296: 1634–5.
